The clinical management of patients with a small volume of prostatic cancer on biopsy: What are the risks of progression?

Clinically localized prostate cancer is associated with a wide variation in biologic behavior, and men with the less aggressive form of the disease may never develop symptoms. There has been a rise in prostate cancer incidence in countries in which the blood test for prostatic‐specific antigen (PSA) is common, and concerns have been expressed that this may be because of the increased detection of indolent disease, subjecting these men to unnecessary treatment and associated side effects. For the current review, the authors conducted a systematic evaluation of the literature regarding the outcomes of men who were diagnosed on the basis of a small volume of cancer in prostatic biopsies. The results indicated that, despite differences in study design and reporting, a significant proportion of patients with microfocal cancer, regardless of how it was defined, had adverse pathologic findings and a significant risk of PSA recurrence after undergoing radical prostatectomy. Biochemical and clinical recurrences also were observed after radiotherapy or watchful waiting. The authors concluded that patients with microfocal carcinoma on biopsy should be advised that their disease is not necessarily “insignificant” and should be counseled accordingly. Cancer 2008. © 2008 American Cancer Society.

[1]  O. Ogawa,et al.  Clinical Significance of Nonpalpable Prostate Cancer with Favorable Biopsy Features in Japanese Men , 2000, European Urology.

[2]  T. H. van der Kwast,et al.  Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance. , 2006, European urology.

[3]  T. Tot,et al.  Prediction of extracapsular extension of prostate cancer based on systematic core biopsies , 2006, Scandinavian journal of urology and nephrology.

[4]  D. Bostwick,et al.  The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. , 1995, The Journal of urology.

[5]  A. Renshaw,et al.  Pathologic findings and prostate specific antigen outcome after radical prostatectomy for patients diagnosed on the basis of a single microscopic focus of prostate carcinoma with a Gleason score ≤ 7 , 2000, Cancer.

[6]  O. Ogawa,et al.  Correlation of initial PSA level and biopsy features with PSA-doubling time in early stage prostate cancers in Japanese men. , 2002, European urology.

[7]  A. Partin,et al.  Ability of sextant biopsies to predict radical prostatectomy stage. , 1998, Urology.

[8]  M. Mason,et al.  The prognostic significance of perineural invasion in prostatic cancer biopsies , 2007, Cancer.

[9]  M. Toublanc,et al.  Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features. , 2005, European urology.

[10]  D. Chan,et al.  Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. , 1998, The Journal of urology.

[11]  B. Carey,et al.  Imaging for prostate cancer. , 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).

[12]  T. van der Kwast,et al.  The clinical significance of a small focus of well‐differentiated carcinoma at prostate biopsy , 2003, BJU international.

[13]  J. Epstein,et al.  Correlation of minute (0.5 MM or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density. , 2003, The Journal of urology.

[14]  H. Fuse,et al.  Preoperative parameters to predict tumor volume in Japanese patients with nonpalpable prostate cancer , 2002, International Journal of Clinical Oncology.

[15]  T. Wilt,et al.  Clinically localised prostate cancer , 2006, BMJ : British Medical Journal.

[16]  J A Smith,et al.  Results of radical prostatectomy in men with clinically localized prostate cancer. , 1996, JAMA.

[17]  Haiqun Lin,et al.  Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma. , 2005, The Journal of urology.

[18]  A. Bardia,et al.  Hand-foot syndrome after dose-dense adjuvant chemotherapy for breast cancer: a case series. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  H. Neuwirth,et al.  Failure of focal prostate cancer on biopsy to predict focal prostate cancer: the importance of prevalence. , 1995, The Journal of urology.

[20]  S. Bott,et al.  Anterior prostate cancer: is it more difficult to diagnose? , 2002, BJU international.

[21]  P. Scardino,et al.  The clinical features of anterior prostate cancers , 2006, BJU international.

[22]  M. Graefen,et al.  Insignificant prostate cancer in radical prostatectomy specimen: time trends and preoperative prediction. , 2003, European urology.

[23]  A. D'Amico,et al.  Impact of multiple biopsy cores on predicting final tumor volume in prostate cancer detected by a single microscopic focus of cancer on biopsy. , 2005, Urology.

[24]  M. Terris,et al.  Prediction of prostate cancer volume using prostate-specific antigen levels, transrectal ultrasound, and systematic sextant biopsies. , 1995, Urology.

[25]  A W Partin,et al.  Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. , 2002, Urology.

[26]  A S Whittemore,et al.  Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer , 1993, Cancer.

[27]  M. Semper,et al.  Adenocarcinomas mínimos de próstata en la biopsia sometidos a prostatectomía radical , 2005 .

[28]  M. Toublanc,et al.  A single positive prostate biopsy in six does not predict a low-volume prostate tumour. , 1996, British journal of urology.

[29]  Rosalie Nolley,et al.  The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? , 2004, The Journal of urology.

[30]  J. Hanley,et al.  Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. , 1999, JAMA.

[31]  M. Montesino Semper,et al.  [Minimal prostatic adenocarcinomas in the biopsy treated with radical prostatectomy]. , 2005, Actas Urológicas Españolas.

[32]  J A Hanley,et al.  Screening for prostate cancer: estimating the magnitude of overdetection. , 1998, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[33]  J. Hugosson,et al.  The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable. , 2004, The Journal of urology.

[34]  P. Walsh,et al.  Pathological stage is higher in older men with clinical stage B1 adenocarcinoma of the prostate. , 1989, The Journal of urology.

[35]  Y. Ono,et al.  Pathological findings of radical prostatectomy specimens in Japanese men diagnosed on single core positive prostate biopsy in eight with a Gleason score less than 4 , 2003, International journal of urology : official journal of the Japanese Urological Association.

[36]  P. Scardino,et al.  Impact of the radical prostatectomy surgical technique and surgeon experience on freedom from cancer recurrence. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  J C Bailar,et al.  Survival rates of patients with prostatic cancer, tumor stage, and differentiation--preliminary report. , 1966, Cancer chemotherapy reports.

[38]  D. Wood,et al.  Single focus of adenocarcinoma in the prostate biopsy specimen is not predictive of the pathologic stage of disease. , 1996, Urology.

[39]  T. Stamey,et al.  Observations on the doubling time of prostate cancer. The use of serial prostate‐specific antigen in patients with untreated disease as a measure of increasing cancer volume , 1993, Cancer.

[40]  R. Manecksha,et al.  Positive apical surgical margins after radical retropubic prostatectomy, truth or artefact? , 2004, Scandinavian journal of urology and nephrology.

[41]  Peter H Gann,et al.  Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. , 2002, Journal of the National Cancer Institute.

[42]  L. Egevad,et al.  Estimation of prostate cancer volume by multiple core biopsies before radical prostatectomy. , 1998, Urology.

[43]  Christopher K. Poulos,et al.  Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens. , 2005, The Journal of urology.

[44]  T. Stamey,et al.  PATTERNS OF PROGRESSION IN PROSTATE CANCER , 1986, The Lancet.

[45]  E. Vaughan,et al.  Microfocal prostate cancer: biopsy cancer volume does not predict actual tumour volume. , 1998, British journal of urology.

[46]  A. Renshaw,et al.  Can the core length involved with prostate cancer identify clinically insignificant disease in low risk patients diagnosed on the basis of a single positive core? , 2003, Urologic oncology.

[47]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[48]  T. H. van der Kwast,et al.  Incidence and follow‐up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years , 2005, Cancer.

[49]  D. Chopin,et al.  [Prognostic value of a positive single ultrasound-guided prostatic biopsy regarding tumor volume and intracapsular nature of prostatic adenocarcinoma]. , 1996, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[50]  John L.P. Thompson,et al.  Missing data , 2004, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[51]  Gleason Df,et al.  Survival rates of patients with prostatic cancer, tumor stage, and differentiation--preliminary report. , 1966 .

[52]  I. H. Chang,et al.  Clinical Significance of a Single-Core Positive Prostate Cancers Detected on Extended Prostate Needle Biopsy , 2006 .

[53]  A. Rademaker,et al.  One core positive prostate biopsy is a poor predictor of cancer volume in the radical prostatectomy specimen. , 1997, The Journal of urology.

[54]  Victor Reuter,et al.  Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. , 2003, The Journal of urology.

[55]  Theodore L. DeWeese,et al.  Localized Prostate Cancer , 2007 .

[56]  T. Stamey,et al.  Core cancer length in ultrasound-guided systematic sextant biopsies: a preoperative evaluation of prostate cancer volume. , 1995, Urology.

[57]  J. Lloreta,et al.  The relationship between tumor volume and the number of positive cores in men undergoing multisite extended biopsy: implication for expectant management. , 2005, The Journal of urology.